Skip to content

US · GSK · DRUG MANUFACTURERS - GENERAL

GSK plc (GSK) intrinsic value and stock valuation

$47.76as of 2026-11-21 · Mkt cap 103.1B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

GSK plc DCF and intrinsic value

InvestorsCraft values GSK with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from GSK’s statements →

GSK plc Graham Number

Graham Number: $22.35d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Drug Manufacturers - General London, GL WC1A 1DG gsk.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$32.7B+6% 5y CAGRd
20112025
Net income
$5.72B-0.1% 5y CAGRd
20112025
Free cash flow
$5.82B-2.2% 5y CAGRd
20112025
Total equity
$15.9B-10.9% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$32.7B$31.4B$30.3B$29.3B$24.7B
Operating income$8.34B$4.02B$6.75B$6.43B$4.36B
Net income$5.72B$2.58B$4.93B$15B$4.39B
EPSd$2.78M$1.24M$2.4M$7.32M$2.71M
Operating cash flow$7.14B$6.55B$7.89B$8.16B$7.95B
Capital expenditure-$-1.32B-$-2.98B-$-1.63B-$-1.41B-$-2.65B
Free cash flow$5.82B$3.57B$6.26B$6.75B$5.3B
Total assets$61B$59.5B$75.2B$60.1B$107.1B
Total debt$17.7B$17B$23B$21B$32.7B
Net debt$14.3B$13.3B$19.2B$17.3B$27B
Total equity$15.9B$13.1B$16.3B$10.1B$28.9B
Cash and short-term investments$3.4B$3.71B$6.61B$7.88B$5.87B
Income statement
20252024202320222021
Revenue$32.7B$31.4B$30.3B$29.3B$24.7B
Cost of revenue$9.02B$9.05B$8.57B$9.55B$8.16B
Gross profit$23.7B$22.3B$21.8B$19.8B$16.5B
Research and development expenses$7.53B$6.4B$6.22B$5.49B$5.02B
Selling, general and administrative expenses$9.09B$11B$9.39B$8.37B$7.07B
Other expenses-$-1.3B$891M-$-590M-$-523M$87M
Operating expenses$15.3B$18.3B$15B$13.3B$12.2B
Cost and expenses$24.3B$27.4B$23.6B$22.9B$20.3B
Interest income$56M$67.4M$40M$64.3M$28M
Interest expense$687M$657.6M$775M$855.5M$784M
Depreciation and amortization$2.31B$2.55B$2.29B$2.15B$2.12B
Ebitda$10.4B$6.67B$9.08B$8.6B$6.49B
Operating income$8.34B$4.02B$6.75B$6.43B$4.36B
Total other income/expenses, net-$-937M-$-544M-$-681M-$-805M-$-758M
Income before tax$7.4B$3.48B$6.06B$5.63B$3.6B
Income tax expense$1.11B$526M$756M$707M$83M
Net income$5.72B$2.58B$4.93B$15B$4.39B
Weighted average shares outstanding$2.03B$2.04B$2.03B$2.01B$1.6B
Weighted average diluted shares outstanding$2.06B$2.07B$2.06B$2.04B$1.62B
Balance sheet
20252024202320222021
Cash and short-term investments$3.4B$3.71B$6.61B$7.88B$5.87B
Net receivables$7.75B$6B$9.44B$6.22B$10.9B
Inventory$5.91B$5.67B$7.01B$5.15B$7.83B
Total current assets$17.5B$17B$23.8B$20.8B$25.3B
Property, plant and equipment, net$10B$10.1B$12.7B$9.62B$14.5B
Goodwill and intangible assets$23.7B$22.5B$27.5B$21.4B$55B
Long-term investments$1.12B$1.21B$2.73B-$-2.61B$4.29B
Total non-current assets$43.5B$42.5B$51.5B$39.4B$81.8B
Total assets$61B$59.5B$75.2B$60.1B$107.1B
Accounts payable$15.4B$3.46B$4.74B$3.87B$6.14B
Short-term debt$3.01B$2.35B$3.59B$3.95B$4.88B
Deferred revenue$0.00$0.00$283M$0.00$415.8M
Total current liabilities$21.4B$21.7B$26.9B$22.8B$32.1B
Long-term debt$14.7B$14.6B$19.4B$17B$27.9B
Deferred revenue, non-current$0.00$165M$323.8M$83M$115.1M
Total non-current liabilities$23.7B$24.7B$32.1B$27.2B$46.2B
Capital lease obligations$0.00$1.1B$1.34B$1.01B$1.1B
Total liabilities$45B$46.4B$58.9B$50.1B$78.2B
Common stock$1.35B$1.35B$1.72B$1.35B$1.82B
Retained earnings$10.2B$7.8B$9.23B$4.36B$13.3B
Accumulated other comprehensive income (loss)$0.00$0.00$2.04B$0.00$869.6M
Total equity$15.9B$13.1B$16.3B$10.1B$28.9B
Total investments$1.13B$1.23B$5.59B$1.54B$4.37B
Total debt$17.7B$17B$23B$21B$32.7B
Net debt$14.3B$13.3B$19.2B$17.3B$27B
Cash flow statement
20252024202320222021
Net income$5.59B$2.95B$6.13B$5.49B$3.52B
Depreciation and amortization$3.7B$2.55B$2.85B$2.64B$2.12B
Stock-based compensation$0.00$344M$0.00$0.00$343M
Change in working capital-$-608.37M$2.09B-$-1.06B-$-1.67B$1.39B
Accounts receivable$0.00$340M-$-806.74M-$-758.78M-$-1.16B
Inventory$0.00-$-294M-$-527.05M-$-331.35M$51M
Accounts payable$0.00$0.00-$-18.65M$608.5M$0.00
Net cash provided by operating activities$7.14B$6.55B$7.89B$8.16B$7.95B
Investments in property, plant and equipment-$-2.92B-$-1.4B-$-2.91B-$-2.78B-$-950M
Acquisitions, net-$-4.37B$1.37B-$-1.72B-$-3.79B$185M
Net cash used for investing activities-$-5.72B-$-1.23B-$-2.4B-$-10.88B-$-1.78B
Common stock issued$14.7M$20M$12.4M$30.8M$21M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid-$-2.51B-$-2.44B-$-2.79B-$-4.27B-$-4B
Net cash used for financing activities-$-1.59B-$-4.73B-$-6.07B$2.05B-$-7.59B
Net change in cash-$-206.06M$545M-$-735.58M-$-1.31B-$-1.44B
Cash at end of period$3.39B$3.4B$3.74B$4.48B$3.82B
Operating cash flow$7.14B$6.55B$7.89B$8.16B$7.95B
Capital expenditure-$-1.32B-$-2.98B-$-1.63B-$-1.41B-$-2.65B
Free cash flow$5.82B$3.57B$6.26B$6.75B$5.3B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About GSK plc

        GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.

        CEO
        Luke Victor Miels
        Employees
        66.84K
        Beta
        0.30

        Explore

        Frequently asked questions

        What is the intrinsic value of GSK plc (GSK)?

        GSK plc (GSK) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is GSK undervalued?

        GSK trades at a price of $47.76 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.